Research Compound Profile

Pinealon

EDR (Glu-Asp-Arg): Khavinson Peptide Bioregulator

Looking for a quick overview? See the Pinealon Snapshot →
Research Areas

Neuroprotection, cognitive function, epigenetic regulation

FDA Status

Never approved; Russian bioregulator (SPIBG)

First Characterized

~2008–2011 (Khavinson et al.)

Routes

Oral (capsules), SC / IM injection, Nasal spray

Overview

Pinealon is a synthetic tripeptide with the amino acid sequence Glu-Asp-Arg (EDR). It belongs to the Russian tradition of "short regulatory peptides" (also called bioregulators or cytomedins) pioneered by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology (SPIBG). Unlike receptor-binding peptides, Pinealon is proposed to act as an epigenetic regulator, entering the cell nucleus and interacting directly with DNA promoter regions to modulate gene expression [1].

Its first clear, PubMed-indexed Western characterizations appeared around 2008–2011, establishing its role in mitigating oxidative stress and modulating cellular viability in neuronal models [2]. Human clinical evidence (drawn from Russian clinical evaluations) covers post-traumatic brain injury (TBI) recovery, cerebroasthenia, and psychoemotional correction in older adults, almost exclusively via the oral route [3].

In the Western research-chemical market, Pinealon is sold as lyophilized powder for reconstitution and injection, as nasal/sublingual spray and, via Qi Supplements (a US distributor), as branded oral Pinealon® capsules and sublingual drops manufactured by SPIBG. The injectable and spray formats in the research market diverge from the oral route emphasized in the clinical literature.

Research Areas and Claims

Pinealon's published evidence is mostly preclinical (cell and animal models) with limited Russian clinical evaluations. Longevity and performance claims circulating in clinic contexts extend well beyond the available data.

  • Neuroprotection / Oxidative Stress Reduction (Preclinical): Peer-reviewed cell studies demonstrate that Pinealon suppresses reactive oxygen species (ROS), activates proliferative processes, and protects neurons from oxidative stress-induced apoptosis. These effects are the most rigorously documented in the published literature [2].

  • Cognitive / Psychoemotional Improvement (Clinical Evaluation): Russian clinical evaluations in elderly patients report improved short- and long-term memory, reduced headache severity, better attention (Bourdon correction test), and improved EEG alpha-index in TBI patients following oral Pinealon supplementation [1][3].

  • Athletic Adaptation (Clinical Evaluation): A clinical evaluation in competitive athletes found improved antioxidant system function, enhanced adaptation to intense training, and favorable changes in immune activation markers after two weeks of oral Pinealon supplementation [1].

  • Memory Enhancement, Anti-Aging, Neurodegeneration Reversal (Clinic Claims): Widespread clinic and marketing claims about reversing neurodegeneration, dramatically improving memory, or achieving anti-aging effects lack support from large-scale, independently replicated randomized controlled trials. The clinical evidence base is limited to small Russian evaluations with no Western RCT verification [1].

Mechanism of Action

Pinealon's proposed mechanism is fundamentally different from receptor-binding peptides. It is hypothesized to act epigenetically, inside the cell nucleus, a model that, while plausible, is based on molecular modeling and in vitro data rather than confirmed human pharmacodynamics.

  1. Nuclear Entry & DNA Binding: The EDR sequence is proposed to enter the cell nucleus and physically bind to major groove motifs in the promoter regions of specific genes. This DNA interaction is hypothesized to directly regulate gene expression and downstream protein synthesis, bypassing conventional receptor-mediated signaling [1].
  2. Antioxidant & Antiapoptotic Gene Activation: At the cellular level, peer-reviewed data shows Pinealon suppresses free radical levels (ROS), modulates the MAPK/ERK signaling pathway, and alters the expression of apoptosis regulators and antioxidant enzymes. The net effect is enhanced neuronal survival under oxidative stress and hypoxia conditions [2].
  3. Relevance to Alzheimer's Pathogenesis: The EDR peptide has been proposed to interfere with pathways implicated in Alzheimer's disease, including amyloid precursor protein (APP) processing, by modulating gene expression at the promoter level, a hypothesis explored in Khavinson's 2020 molecular review [1].

Clinical Evidence

Unlike Western pharmaceuticals, Russian peptide bioregulators rarely progress through large-scale, randomized double-blind Phase III trials indexed in PubMed. The human evidence below relies on Russian clinical evaluations summarized in Khavinson's PubMed/PMC-indexed review papers, not standalone peer-reviewed RCT publications.

Elderly CNS (2008)

Design Clinical Evaluation; Elderly patients with psycho-emotional and CNS disorders
Route Oral capsules
Duration 2 weeks
Key Finding Improved short- and long-term memory; decreased severity of psychoemotional distress and CNS functional decline
Ref [3]

Post-TBI (summarized)

Design Clinical Evaluation; 72 patients with post-TBI consequences
Route Oral capsules
Duration 20–30 days
Key Finding Improved memory, reduced headache duration/intensity, better attention (Bourdon test), improved EEG alpha-index
Ref [1]

Athletes (~2012)

Design Clinical Evaluation; Competitive athletes
Route Oral capsules
Duration 2 weeks
Key Finding Improved antioxidant function, enhanced training adaptation, favorable immune activation markers, fewer acute respiratory diseases during training blocks
Ref [1]

Missing-Trials Note: The majority of specific clinical outcomes for Pinealon are derived from summaries in Khavinson's PubMed-indexed review papers, not standalone peer-reviewed RCTs. No large-scale, independently replicated randomized controlled trials exist in the Western literature. All clinical evidence referenced here uses the oral route; the injectable and spray formats sold in the Western research market are not represented in published human clinical data [1][3].

Administration Methods

  • Oral (Capsules): The route used in all referenced human clinical evaluations. Dosing in studies: 0.1 mg per capsule, two capsules twice daily for 20–30 days (TBI), or two capsules daily for 2 weeks (elderly CNS, athletes). Available as branded Pinealon® capsules (SPIBG / Qi Supplements).
  • Subcutaneous (SC) / Intramuscular (IM): Used in in vivo animal experiments. In the Western research-chemical market, most vendors supply lyophilized powder intended for reconstitution and SC/IM injection, though this diverges from the oral route validated in the human evidence.
  • Nasal / Sublingual Spray: Available pre-mixed from Umbrella Labs (100mg in 15mL, 1mg/spray). Bioavailability via intranasal or sublingual routes for this tripeptide has not been established in published pharmacokinetic studies.

Important Safety & Regulatory Information

  • Never Approved in Western Medicine: Pinealon has never received FDA approval or any equivalent regulatory clearance for human use in Western markets. It is not a licensed pharmaceutical. In Russia, it is marketed under the Pinealon® brand by SPIBG, operating under a different regulatory framework.
  • No Standardized Dosing: No guideline-endorsed dosing schedule exists for Pinealon in Western medicine for any indication. Doses used in Russian clinical evaluations (0.1–0.2 mg/capsule oral) are far lower than the milligram-scale concentrations supplied by most Western research vendors for injection.
  • Injectable Format Not Clinically Validated: The lyophilized powder reconstituted for SC/IM injection (the predominant format in the Western research market) has no published human pharmacokinetic data and is not the route used in any referenced clinical evaluation. Bioavailability, safety profile, and appropriate dosing for injectable formats are unknown.
  • Evidence Quality Limitations: All referenced human clinical evidence comes from Russian clinical evaluations summarized in review papers by the same research group (Khavinson). Independent replication by Western research groups is absent. The evidence base should be interpreted with significant caution.

Market Overview

Please note: Data collected February 2026 via independent web search; no Finnrick vendor list exists for Pinealon. All products sold strictly as research chemicals (or, via Qi Supplements, as original Russian SPIBG Pinealon® brand products). Prices fluctuate by volume, batch, and presentation.

Injectable

Lyophilized Powder

Reconstituted for SC / IM injection. Standard vial size: 20mg.

  • Price Range: $2.93 – $4.90 / mg
  • Best $/mg: Peptide Works $2.93/mg (20mg)
  • Vendors: 9 surveyed

Nasal Spray

Pre-Mixed Liquid

Umbrella Labs only. 100mg in 15mL (1mg/spray). Lowest $/mg of all formats.

  • Price: $0.90 / mg
  • Size: 100mg (15mL bottle)
  • Vendors: 1 surveyed

Oral / Branded

Capsules / Drops

Original Russian Pinealon® (SPIBG). The route used in all referenced clinical evaluations.

  • Price: ~$9 – $11 / mg (est.)
  • Sizes: 20-cap or 60-cap (mg/cap not disclosed)
  • Vendors: Qi Supplements (US distributor)

Vendor Directory

Data collected February 2026. Tables split by formulation. No Finnrick vendor ratings available for Pinealon.

SC / IM Injection: Lyophilized Powder (sorted by $/mg)

BioLongevity Labs

Size (mg) 20
Price $48.98 *
$/mg $2.45 *

Peptide Works

Size (mg) 20
Price $58.64
$/mg $2.93

Biotech Peptides

Size (mg) 20
Price $68.00
$/mg $3.40

Modern Aminos

Size (mg) 20
Price $68.00
$/mg $3.40 †

Pura Peptides

Size (mg) 20
Price $70.00 ‡
$/mg $3.50 ‡

Peptide Works (Kit)

Size (mg) 20
Price $70.09
$/mg $3.50

Peptide Sciences

Size (mg) 20
Price $75.00
$/mg $3.75

Core Peptides

Size (mg) 20
Price $75.00
$/mg $3.75

Planet Peptide

Size (mg) 20
Price $75.00
$/mg $3.75

BioEdge Research Labs

Size (mg) 10
Price $49.00 *
$/mg $4.90 *

* Sale price active at time of data collection; verify current pricing before purchasing. BioLongevity Labs regular price $69.97/20mg ($3.50/mg); BioEdge regular price $54.00/10mg ($5.40/mg). Peptide Works Kit ($70.09) includes 20mg vial, 10mL bacteriostatic water, and syringes. Biotech Peptides bulk: 5–9 units $64.60/ea, 10+ $61.20/ea. Core Peptides bulk: 5–8 units $71.25/ea, 9+ $67.50/ea. Peptide Sciences bulk: 5 units $73.00/ea, 10 units $68.00/ea.
† Modern Aminos: Price confirmed via search snippet; direct product URL inaccessible at time of research (Cloudflare protection).
‡ Pura Peptides: Site requires age verification; price and size sourced from search snippet only, not confirmed via direct product page.

Nasal / Sublingual Spray: Pre-Mixed Liquid

Umbrella Labs

Format Pre-mixed spray (1mg/spray, 15mL)
Size (mg) 100
Price $89.99
$/mg $0.90
Website umbrellalabs.is

Umbrella Labs does not offer Pinealon in lyophilized powder form; spray is the only format available from this vendor. Store cold, do not freeze.

Oral Capsules & Sublingual Drops: Pinealon® Brand (SPIBG / Qi Supplements)

Qi Supplements

Format Oral capsules (Pinealon®)
Count 20 caps (~4mg est.)
Price $45.00
$/mg (est.) ~$11.25 §

Qi Supplements

Format Oral capsules (Pinealon®)
Count 60 caps (~12mg est.)
Price $109.00
$/mg (est.) ~$9.08 §

Qi Supplements

Format Sublingual drops (Pinealon®): PRE-ORDER
Count 10mL bottle
Price $44.99
$/mg (est.) — §

* Data Notes: Data collected February 2026 via independent web search. All injectable and spray products sold strictly for in-vitro research purposes. Prices subject to change. $/mg calculated from listed catalog price divided by total mg per unit where disclosed.
§ Qi Supplements oral capsule mg per unit is not officially disclosed by SPIBG; estimated at 0.2mg/capsule based on standard SPIBG dosing protocol. Sublingual drops concentration not disclosed (pre-order status at time of research). $/mg for oral capsules should be treated as approximate.

References

  1. Khavinson V, et al. "EDR Peptide: Possible Mechanism of Gene Expression and Protein Synthesis Regulation Involved in the Pathogenesis of Alzheimer's Disease." Molecules. 2020. PMC7795577
  2. Khavinson V, Ribakova Y, et al. "Pinealon increases cell viability by suppression of free radical levels and activating proliferative processes." Rejuvenation Res. 2011. PubMed 21978084
  3. Balashova SN, et al. "Application of peptide bioregulators by elderly people suffering from psycho-emotional disorders." Adv Gerontol. 2008. PubMed 19432183
Monthly Digest

Stay ahead of the market

New peptide profiles, vendor pricing shifts, and research updates. No spam, unsubscribe anytime.